Novartis completes $2.1bn acquisition of Endocyte to boost cancer treatment capabilities
Swiss pharmaceutical giant Novartis has officially closed its $2.1 billion acquisition of US-based biopharma company Endocyte, solidifying its position as a leader in radiopharmaceuticals for cancer treatment. The deal, first announced in October 2018, was finalised following shareholder approval earlier this week. A strategic move into radioligand and CAR-T therapies Endocyte specialises in developing radioligand […]